Previous 10 | Next 10 |
- Total Revenues of $270.2 Million, Cabozantinib Franchise Revenues of $227.2 Million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an ...
Exelixis (NASDAQ:EXEL) is scheduled to announce Q1 earnings results on Thursday, May 6th, after market close.The consensus EPS Estimate is $0.03 (-84.2% Y/Y) and the consensus Revenue Estimate is $266.75M (+17.6% Y/Y).Over the last 2 years, EXEL has beaten EPS estimates 100% of the time and h...
- Early clinical data of naked monoclonal antibodies support safety of targeting anti-Müllerian hormone receptor 2 (AMHR2), an oncology target of interest - - Antibody-drug conjugates (ADCs) targeting AMHR2 could provide clinical efficacy in gynecologic, colorectal and ot...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p.m. EDT / 2:00...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Short review of IDNA. For further details see: Healthcare Dashboard For April And Focus On IDNA
Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...
The FDA has accepted Exelixis' (EXEL) Investigational New Drug Application ((IND)) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors.As a next-generation tissue factor-targeting antibody-drug conjugate ((A...
– Promising preclinical data suggest best-in-class potential for XB002, a next-generation tissue factor-targeting antibody-drug conjugate – – Phase 1 clinical trial expected to begin in Q2 2021 – Exelixis, Inc. (Nasdaq: EXEL) t...
Exelixis ([[EXEL]] +3.7%) announced that its partner Ipsen ([[IPSEY]] +3.9%) has secured the European Commission approval for Cabometyx (cabozantinib)/ Opdivo (nivolumab) combination as a first-line treatment in advanced renal cell carcinoma.Cabometyx and Opdivo will now be commerci...
– Approval based on CheckMate -9ER trial, in which CABOMETYX in combination with OPDIVO doubled progression-free survival and objective response rate while significantly improving overall survival versus sunitinib – Exelixis, Inc. (Nasdaq: EXEL) today a...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...